Wissenschaftliche Publikationen

Prof. Dr. med. Hartmut Porst ist Autor von über 300 Publikationen und Buchbeiträgen

Wissenschaftliche Publikationen 1978 - 1986

  1. Porst H.: Das orthostatische Verhalten beim Vorhofseptumdefekt. (Prä- und postoperative sphygmographische Kreislaufuntersuchungen an 60 Patienten): Inauguraldissertation, Chirugische Universitätsklinik Erlangen - Nürnberg, 1978)

  2. Altwein, J.E., Porst H.: Möglichkeiten der konservativen Therapie der Prostatahyperplasie. Klin. Exp. Urol. 4, 157 - 164, 1982

  3. Porst H., Altwein, J.E.: Problematik der Diagnostik und Therapie der vaskulären erektilen Impotenz. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 33. Tagung, 224226, 1982, Springer-Verlag, Berlin-Heidelberg-New York

  4. Porst H., Bähren, W., Altwein, J.E.: Diagnostik und Therapiemöglichkeiten der vaskulären erektilen Impotenz. Urol. int. 38, 5 - 11, 1983

  5. Porst H., Lenz, M., Bähren, W., Altwein, J.E.: Gefäßveränderungen bei primärer und sekundärer Impotenz. Akt. Urol. 14, 281 - 285, 1983 6. Porst, H., Bähren, W., Altwein, J.E., Thon, W.: Selektive Verödung der Varikozele- Die Therapiemethode der Zukunft? Therapiewoche 33, 3892 - 3895, 1983

  6. Bähren, W., Lenz, M., Porst H., Wierschin, W.: Nebenwirkungen, Komplikationen und Kontraindikationen der perkutanen Sklerotherapie der V. spermatica zur Behandlung der idiopathischen Varikozele. Fortsch. Röntgenstr. 138, 2, 172 - 179, 1983

  7. Porst H., Bähren, W., Lenz, M., Altwein, J.E.: Percutaneous sclerotherapy of varicoceles – an alternative to conventional surgical methods. Br. J. Urol. 56, 73 - 78, 1984

  8. Porst H., Thon, W., Bach, D., Altwein, J.E.: Penile Revaskularisationschirurgie bei vaskulärer Impotenz. Urologe A 23, 258 - 266, 1984

  9. Porst H., Altwein, J.E., Mayer, R., Bach, D.: Erektions- und Ejakulationsstörungen nach retroperitonealer Lymphadenektomie (RLA) beim nicht-seminomatösen Hodentumor. Urologe A 23, 324 - 328, 1984

  10. Bähren, W., Lenz, M., Porst H., Wierschin, W.: Arteriographische Diagnostik der erektilen Impotenz.Fortschr. Röntgenstr. 140, 4, 447 - 452, 1984

  11. Altwein, J.E., Porst H.: Das infiltrierende Harnblasenkarzinom: Probleme der radikalen und palliativen Behandlung. Akt. Urol. 15, 196 - 205, 1984

  12. Porst H., Altwein, J.E.: Revaskularisationschirurgie versus Prothesenchirurgie bei vaskulärer Impotenz. Helv. chir. Acta 51, 369 - 374, 1984

  13. Porst H., Altwein, J.E., Oberneder, M.: Traumatische Impotenz - Ursachen, Diagnostik, Therapiemöglichkeiten. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 35.Tagung, 137 - 141, 1984 Springer-Verlag, Berlin-Heidelberg-New York

  14. Porst H., Bähren, W., Altwein, J.E.: Diagnostik und Therapie der vaskulären Impotenz. In Loose, D.A. (Hrsg.) Periodica Angiologica 6, 42 - 50, 1984, Einhorn-Presse-Verlag

  15. Porst H., Altwein, J.E.: Diagnostik und Therapie der vaskulären Erektionsstörungen. Werkhefte der Universität Tübingen, Reihe D Medizin 5, 23 - 45, 1984, Attempto Verlag, Tübingen

  16. Porst H., Mayer, R., Bach, D., Altwein, J.E.: Congenital and acquired penile curvatures: diagnosis and outcome with the Nesbit procedure. Urol. int. 40, 206 - 210, 1985

  17. Porst H., Mayer, R.: Ausscheidungsurographie - Aktuelle Bestandsaufnahme bei einem konventionellen Diagnostikum. Forschr. Med. 30, 755 - 758, 1985

  18. Porst H., Mayer, R., Brühl, P.: " Der interessante Fall" - Angiomyolipome der Niere. Akt. Urol. 16, 262 - 268, 1985

  19. Porst H., Altwein, J.E., Bach, D., Thon, W.: Dynamic cavernosography: Venous outflow studies of cavernous bodies. J. Urol. 134, 276 - 279, 1985

  20. Porst H., Bach, D., Thon, W., Altwein, J.E.: Erektile Dysfunktion - Aktuelle Aspekte der Ätiologie, Diagnostik und Therapie. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 36. Tagung, 489 - 494, 1985, Springer-Verlag, Berlin-Heidelberg-New York-Tokyo

  21. Porst H., Mayer, R., Brühl, P.: Diagnostische und therapeutische Problematik der renalen Onkozytome. Urologe A 25, 38 - 42, 1986

  22. Porst H., Mayer, R., Clauß, W.: Nephrotoxizität ionischer und nichtionischer Kontrastmittel in der selektiven Renovasographie. Urologe A 15, 120 - 123, 1986

  23. Porst H.: Cavernosography - Venous outflow studies of the penis. In: Virag, R., and H.: Proceedings of the First World Meeting on Impotence, Editions du CERI, pp. 159 - 162, 1986, Paris

  24. Leipner, N., Porst H., Köster, O., Nadstawek, J.: DSA und konventionelle Angiographie bei der angiographischen Diagnostik der Impotentia coeundi. Fortschr. Röntgenstr. 144, 5, 516 – 522, 1986

  25. Porst H., van Ahlen, H., Leipner, N., Köster, O.: Dynamische Cavernosographie. Fortschr. Röntenstr. 145, 1, 80 - 87, 1986

  26. Tackmann, W., Porst H.: Der Bulbokavernosusreflex bei Kontrollen und Patienten mit Potenzstörungen. Zeitschr. EEG-EMG 17, 113 - 172, 1986

  27. Porst H., Mayer, R., Brühl, P.: Die Niere als Manifestationsort seltener benigner und maligner Neoplasien. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 37.Tagung, 598 - 600, 1986, Georg-Thieme-Verlag, Stuttgart-New York

Wissenschaftliche Publikationen seit der Habilitation 1986

  1. Porst H., van Ahlen, H., Mayer, R., Brühl, P.: Klinik der xanthogranulomatösen Pyelonephritis. Akt. Urol. 18.30 - 35, 1987

  2. van Ahlen, H., Brühl, P., Porst H.: Das akute Skrotum beim Kind.DMW 112, 231 - 233, 1987

  3. van Ahlen, H., Brühl, P., Porst H.: Behandlungskonzepte bei kloakalen Mißbildungen. Akt. Urol. 18, 61 - 65, 1987

  4. Porst H.: Diagnostik und Therapiemöglichkeiten der erektilen Dysfunktion (inarabisch). ARAB MEDICO, 5. Jahrgang, Heft 2, 1987

  5. Porst H., van Ahlen, H., Köster, O.: Penisangiographie und Penis-Dopplersonographie unter Papaverinprovokation. Symposiumsband, 10. Internationales Symposium Ludwig-Boltzmann-Institut zur Erforschung der Infektionen und Geschwülste des Harntraktes, S. 351 - 356, 1987, Wien

  6. Porst H., van Ahlen, H.: Indikation, Technik, Ergebnisse und Komplikationen der dynamischen Cavernosographie und Cavernosometrie. Symposiumsband, 10. Internationales Symposium Ludwig-Boltzmann-Institut zur Erforschung der Infektionen und Geschwülste des Harntraktes, S. 365 - 370, 1987, Wien

  7. van Ahlen, H., Nicolas, V., Brühl, P., Porst H.: Zur aktuellen Diagnostik des kindlichen Nierentraumas: Konsequenzen für die Therapieplanung. Urologe A 26, 88 - 93, 1987

  8. Porst H., van Ahlen, H., Tackmann, W., Köster, O.l., Vahlensieck, W.: Ätiologie und Therapiemöglichkeiten der posttraumatischen erektilen Impotenz. Akt. Traumatol. 17, 196 - 203, 1987

  9. Porst H., van Ahlen, H., Vahlensieck, W.: Relevance of Dynamic Cavernoso-graphy to the Diagnosis of Venous Incompetence in Erectile Dysfunction. J. Urol. 137, 1163 - 1167, 1987

  10. Tackmann, W., Porst H.: Diagnostik neurogener Potenzstörungen mit Hilfe des Bulbo-cavernosusreflexes und somatosensorisch evozierter Potentiale nach Stimulation des Nervus pudendus. Nervenarzt 58, 292 - 299, 1987

  11. van Ahlen, H., Dvorak, O., Schlolaut, K.H., Brühl, P., Porst H.: Das Hämangiom der Niere Diagnostische und therapeutische Probleme. Z. Urol. Nephrol. 80, 459 - 466, 1987

  12. Porst H., Winter, P., Jäger, N., Mayer, R.: Klinische Relevanz der Lymphadenektomie beim hypernephroiden Nierenzellkarzinom - Analyse von 255 Tumornephrektomien. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 38. Tagung, 25 - 27, 1987, Springer-Verlag, Berlin- Heidelberg-New York

  13. Schäfer, R.M., Jäger, N., Porst H., Vahlensieck, W.: Der primär extragonadale (retroperitoneale) Keimzelltumor - Ein prognostisch ungünstiges Kriterium? Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 38. Tagung, 54 – 55, 1987, Springer-Verlag, Berlin-Heidelberg-New York

  14. van Ahlen, H., von Stauffenberg, A., Porst H., Vahlensieck, W.: Inguinaler Progreß von Hodentumoren im Stadium I. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 38. Tagung, 60 - 61, Springer-Verlag, 1987 Berlin-Heidelberg-New York

  15. Jäger, N., Molitor, D., Porst H., Vahlensieck, W.: Ursachen, Prävention und Therapie der Lymphocele nach retroperitonealer Lymphadenektomie (RLA) beim Keimzelltumor. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 38. Tagung, 157 - 158, 1987, Springer-Verlag, Berlin-Heidelberg-New York

  16. Schäfer, M., Brühl, P., Liappis, N., Porst H.: Elektrolyte und Glycin im Serum bei transurethraler Prostataresektion mit Glycinspülung. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 38. Tagung, 483 - 484, 1987 Springer-Verlag, Berlin-Heidelberg-New York

  17. Porst H., van Ahlen, H., Vahlensieck, W.: Der bilaterale Hodentumor - Analyse von 40 eigenen Fällen. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 38. Tagung, 492 - 494, 1987 Springer-Verlag, Berlin-Heidelberg-New York

  18. Porst H., Tackmann, W., van Ahlen, H.: Bulbokavernosusreflex-Latenzzeitmessung (BCR) und somatosensorisch evozierte Potentiale (SSEP) in der Diagnostik der erektilen Dysfunktion. Akt. Urol. 18, 198 - 202, 1987

  19. van Ahlen, H., Brühl, P., Porst H.: Das stumpfe Nierentrauma im Kindesalter.Z. Kinderchirurgie 42, 299 - 303, 1987

  20. Porst, H., van Ahlen, H.: Dynamic cavernosonography and intracavernous drug testing in the diagnosis of erectile dysfunction. Urologe A 26(3): 152-7, 1987

  21. Takmann, W., Vogel, P., Porst H.: Somatosensory evoked potentials afterstimulation of the dorsal penile nerve: normative data and results from 145 patients with erectile dysfunction. Eur-Neurol. 27(4): 245-50. 1987

Wissenschaftliche Publikationen 1988

  1. Porst, H., van Ahlen, H.: Stellenwert nächtlicher peniler Tumeszenz- und Rigiditätsmessungen (NPT) mit dem Rigiscan ® bei erektiler Dysfunktion. Akt. Urol. 19, 21 - 25, 1988

  2. Porst, H.: Die erektile Dysfunktion Z.f. Allgemeinmedizin 64, 325 - 333, 1988

  3. Schäfer, M., Brühl, P., Liappis, N., Porst, H.: Elektrolyte und Gycin im Serum bei transurethraler Prostataresektion mit Glycinspülung. Urologe B 28, 85 - 87, 1988

  4. Porst, H., van Ahlen, H., Köster, O., Schlolaut, K.H.: Vergleich von Papaverin-induzierter Dopplersonsographie und Angiographie in der Diagnostik der erektilen Dysfunktion. Urologe A 27, 8 - 13, 1988

  5. Porst, H.: Stellenwert von Prostaglandin E1 (PGE1) in der Diagnostik der erektilen Dysfunktion (ED) im Vergleich zu Papaverin und Papaverin/Phentolamin bei 61 Patienten mit ED, Urologe A 27, 22 - 26, 1988

  6. Porst, H., Weiske, H.-W., Epple, W.: Komplette Schwellkörperseparation mit Penisdeviation - ein Epispadieäquivalent. Urologe A 27, 49 - 53, 1988

  7. Porst, H., Tackmann, W., van Ahlen, H.: Neurophysiological Investigations in Potent and Impotent Men. Br. J. Urol. 61, 445 - 450, 1988

  8. van Ahlen, H., Brühl, P., Bockisch, A., Emons, D., Porst, H.: Die ektopeUreterocele - Diagnostik und Therapie. Z. Urol. Nephrol. 81, 141 - 151, 1988

  9. van Ahlen, H., Probst, E., Boldt, I., Winter, P., von Stauffenberg, A., Porst, H., Jäger, N.: Hirnmetastasen beim Hodentumor. Akt. Urol. 19, 187 - 190, 1988

  10. Porst, H., Höwing, M.: Zu Klinik und Verlauf des fortgeschrittenenProstatakarzinoms - Ergebnisse einer retrospektiven Studie. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 39. Tagung, 60 62, 1988, Springer-Verlag, Berlin-Heidelberg-New York

  11. Porst, H., Winter, P., van Ahlen, H., von Stauffenberg, A.: Anforderungen derPolychemotherapie an eine urologische Allgemeinstation. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 39. Tagung, 60 - 62, 1988, Springer-Verlag, Berlin-Heidelberg-New York

  12. Porst, H., Tackmann, W., van Ahlen, H.: Stellenwert neurophysiologischerUntersuchungen bei erektiler Dysfunktion (ED) - Ergebnisse der BCR-Latenzzeitmessung und der somatosensorisch evozierten Potentiale (SSEP) bei über 250 Patienten.Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 39. Tagung, 434 - 435, 1988, Springer-Verlag, Berlin-Heidelberg-New York

  13. Porst, H.: Befundinterpretation bildgebender Verfahren bei der Diagnostik von Erektionsstörungen. Verhandlungsbericht der Deutschen Gesellschaft fürUrologie, 39. Tagung, 1988, Springer-Verlag, Berlin-Heidelberg-New York

  14. van Ahlen, H., Porst, H., Löcherbach-Zawadzky, A., Klingmüller, D.: Störungen der Hypothalamus-Hypophysen-Gonadenachse und erektile Impotenz. DMW 113, 1047 - 1052, 1988

  15. Tackmann, W., Porst, H., van Ahlen, H.: Bulbocavernosus reflex latencies andsomatosensory evoked potentials after pudendal nerve stimulation in thediagnosis of impotence. J. Neurol 235, 219 - 225, 1988

  16. Porst, H.: Aktuelle Diagnostik und Behandlungskonzepte von Erektionsstörungen. In: Schirren, C. und Semm, K.: Fortschritte der Fertilitätsforschung, Bd. 16, 34 – 49, Grosse Verlag, 1988

  17. Krahe, T., Leipner, N., Porst, H.: Echomorphologie der Hodentumoren. Fortschr. Röntgenstr. 148, 6, 609 - 614, 1988

  18. van Ahlen, H., von Stauffenberg, A., Porst, H., Vahlensieck, W.: Inguinale Metastasierung von Hodentumoren im Stadium I. Urologe A 27, 275 - 278, 1988

  19. van Ahlen, H., Bruhl, P., Porst, H.: Pediatric blunt renal trauma-surgical of conservative treatment? Eur. Urol., 14(5): 407-11, 1988

Wissenschaftliche Publikationen 1989

  1. Porst, H., Weller, St.: Vasoaktive Substanzen bei erektiler Dysfunktion (ED), - Ergebnisse einer Umfrage und Literaturübersicht. Urologe B 29, 10 - 14, 1989

  2. Porst, H.: Prostaglandin E1 bei erektiler Dysfunktion. Urologe A 28, 94 - 98, 1989

  3. Porst, H., van Ahlen, H.,: Pharmakon-induzierte Priapismen – Ein Erfahrungsbericht über 101 Fälle. Urologe A 28, 84 - 87, 1989

  4. Porst, H.: Korporoplastik angeborener und erworbener Penisdeviationen. Urologe A 28, 168-171, 1989

  5. Porst, H., Ebeling, L.: Erektile Dysfunktion. Übersicht und aktueller Stand vonDiagnostik und Therapie. Fortschr. Med. 107, 3, 88 - 93, 1989

  6. Molderings, G.J., Göthert, M., van Ahlen, H., Porst, H.: Noradrenalin release in human corpus cavernosum and its modulation via presynaptic alpha-2 adrenoceptors. Fundam. Clin. Pharmacol. 3, 497 - 504, 1989

  7. Porst, H.: Angiographie und DSA - Spezielle Applikationen im Genitalbereich. In: Eickenberg, H.U. und Engelmann U.H. (Hrsg.) Uro-Imaging, 92-105, Schnetztor-Verlag, 1989

  8. Winter, P., Porst, H., Meybehm, M., Hermanns, M., Köster, O.: Das kavernöseHämangiom der Harnblase. Akt. Urol. 20, 48 - 50, 1989

  9. Porst, H., van Ahlen, H., Block, T., Halbig, W., Hautmann, R., Löchner-Ernst, D., Rudnick, J., Stähler, G., Weber, H.M., Weidner, W., Weiske, W.H.: Intracavernous selfinjection of Prostaglandin E1 in the therapy of erectile dysfunction. VASA Suppl. 28, 50 - 56, 1989

Wissenschaftliche Publikationen 1990

  1. Porst, H.: Pharmakoangiographie und Pharmakoaniodynographie des Penis bei erektiler Dysfunktion. Urologe A 29, 120 - 125, 1990

  2. Porst, H., van Ahlen, H., Block, T., Halbig, W., Hautmann, R., Löchner-Ernst, D., Rudnick, J. Stähler, G., Weber, H.M., Weidner, W., Weiske, W.H.: Intracavernous selfinjection therapy with Prostaglandin E1 - Results of a Multicenter Study with 189 Patients. Int. J. Impotence Res. 2, Suppl. 2, 259 - 260, 1990

  3. Porst, H.: Hemodynamic Evaluation of Penile Circulation with Duplex-Sonography and Colour Doppler - Results in 133 Patients. Int. J. Impotence Res. 2, Suppl. 2, 212 - 213, 1990

  4. Porst, H.: Diagnostic Use and Side-Effects of Vasoactive Drugs - A Report on over 2100 Patients with Erectile Failure. Int. J. Impotence Res. 2. Suppl. 2. 222 - 223, 1990

  5. Fabra, M., Porst, H., Schneider, E.: BCR-Latencies and SSEP in Erectile Failure Sophisticated Science or Investigaions of Clinical Relevance? Report on over 200 Patients. Int. J. Impotence Res. 2, Suppl. 2, 179 - 180, 1990

  6. Nicolas, V., Spielmann, R., Maas, R., Bressel, M., Wagner, B., Porst, H., Bucheler, E.: The diagnostic value of MR tomography following gadolinium-DTPA compared to computed tomography in bladder tumors. RofoFortschr. Geb. Rontgenstr. Neuen. Bildgeb. Verfahren. 153(2): 197-203, 1990

Wissenschaftliche Publikationen 1992

  1. Fabra, M., Porst, H., Schneider, E.: Single Potential Analysis of CavernousElectric Activity (SPACE) findings in cavernous insufficiency. Int. J. Impotence Res.4, Suppl. 2, A 24, 1992

  2. Porst, H.: Comparison of the outcome of PGE1-test and pharmacocavernoso-graphy in 356 patients with erectile failure. Int. J. Impotence Res. 4, Suppl. 2, A 57, 1992

  3. Porst, H., Loroch, R.: Penile Duplex-sonography in erectile failure and peniledeviations - A critical study in 622 patients. Int. J. Impotence Res. 4, Suppl. 2, A 72, 1992

  4. Porst, H.: Prostaglandin E1 in male impotence its diagnostic and therapeutic use in 2000 patients. Int. J. Impotence Res. 4, Suppl. 2, A 88, 1992

  5. Porst, H.: Pge1 and the NO-donor SIN – 1 in erectile failure a diagnostic cross-over study in 40 patients. Int. J. Impotence Res. 4, Suppl.2, A 91, 1992

  6. Porst, H.: Acceptance and satisfaction with the Osbon ErecAidSystem - results in 59 patients with erectile failure of varied etiology. Int. J. Impotence Res. 4, Suppl. 2, A 104, 1992

  7. Fabra, M., Porst, H., Schneider, E.: Mononeurophathy of pudendal nerve in alcoholic patients with erectile dysfunction? an electrophysiological study on bulbocavernosus-reflex-latencies EMG and motor nerve conduction velocity of pereoneal nerve. Int. J. Impotence Res. 4, Suppl. 2. p 18, 1992

Wissenschaftliche Publikationen 1993

  1. Porst, H.: Prostaglandin E1 and the Nitric Oxide Donor Linsidomine for ErectileFailure: A Diagnostic Comparative Study of 40 Patients. J. Urology, Vol. 149, 1280-1283, 1993

  2. Porst, H.: Nitroglycerin-salbe bei erektiler Impotenz? DMW 118, 203, 1993

  3. Stief, C.G., Juenemann, K.P., Porst, H., Müller, S.C., Weidner, W., Weiske, W.H., Wetterauer, U.,: Die intrakavernöse Anwendung verschiedener Substanzen zur Schwellkörperauto-injektionstherapie-Standortbestimmung. Urologe B, 33: 2 - 5, Springer-Verlag, 1993

  4. Porst, H.: Komplikationen vasoaktiver Substanzen in der Diagnostik und Therapie der erektilen Dysfunktion (ED). Urologe B, 33: 13 - 18, Springer-Verlag, 1993

  5. Porst, H.: Die Duplexsonographie des Penis Urologe A, 32: 242 - 249, Springer- Verlag, 1993

  6. Fabra, M., Prost, H., Schneider, E., Bressel, M.: Singel potentials analysis ofcavernous electric activity (SPACE). Findings before and after surgical dissection of the cavernous nerves within the scope of radical prostatectomy. Urologe A 32(2): 145-50, 1993

  7. Fabra, M., Frieling, A., Porst, H., Schneider, E.: Single potential analysis of corpus-cavernosum- EMG. Reproducibility, provocability, age-dependence. Int. J. Impotence Res. 6, Suppl.1, D 50

Wissenschaftliche Publikationen 1994

  1. Porst, H., Buvat, J, Hauri, D., Krotovsky, G.S., Meuleman, E.J.H., Michal, V.,Wagner, G., Wespes, E.: Self-injecion therapy with prostaglandin E1 - Long-term results of an international multicenter study according to the GCP-standard. Int. J. Impotence Res. 6, Suppl. 1, D 108, 1994

  2. Porst, H.: Ten Years of Experience with Various Vasoactive Drugs –Comparative Studies in over 4000 patients. Int. J. Impotence Res. 6, Suppl. 1,D 149, 1994

Wissenschaftliche Publikationen 1995

Fabra, M., Johanns, A, Porst, H., Schneider, E.: Provocability in corpus cavernosum EMG compared to other neurophysiological and vascular parameters in 72 diabetics with erectile dysfunction. Int. J. Impot. Res. Vol.7, Suppl.1, 26:O21, 1995

Wissenschaftliche Publikationen 1996

  1. Porst, H.: Orale und intracavernöse Pharmakotherapie, TW Urologie/Nephrologie 8, Heft 2, Seite 88-94, 1996

  2. Porst, H., Derouet, H., Idzikowski, M., Hess, H., Knispel, H.H., Moll, V.K.G., Neter, M., Six, G., Stief, C.G., Vradelis, V., Wetterauer, U.: Oral Phentolamin (Vasomax®) in Erectile Dysfunction - Results of a German Multicenter-Study in 177 Patients. Int. J. Impotence Res., Vol.8, No.3, 117:A72, 1996

  3. Porst, H., Editorial Comment to: AMS 700 CX inflatable penile implants for Peyronie's disease: functional results morbidity and patient-partner satisfaction by Montorsi et al. Int. J. Impotence Res. Vol. 8, No. 2, p.85-86, 1996

  4. Porst, H., Abbou, C.C., Amar, E., Devaux, P. ,Flam, T.A., Gesundheit, N., Hall, M., Lycklama à Nijeholt, A.A.B., Lynch, S.F., Morgan, R.J., Müller, S.C., Pryor, J.P., Ryan, P.C., Williams, G., Witzsch, U.K.F., Place, V.A. and the European VIVUS-MUSE® Study Group: Transurethral Alprostadil for the treatment of chronic erectile dysfunction: the EuropeanExperience. Int. J. Impotence Res. 8, No. 3, D35, 1996

  5. Porst, H., Buvat, J., Meuleman, E.J.H., Michal, V., Wagner, G.: Final results of aprospective multicenter-study with self-injection therapy with PGE1 after 4 years of follow- up. Int. J. Impotence Res. 8 No.3:151, D118, 1996

  6. Porst, H.: Corporoplasty in Congenital and Acquired Penile Curvatures – Personal Results in 308 Patients. Int. J. Impotence Res. Vol.8, No.3, 175:D212, 1996

  7. Porst, H.: Review Article: The Rationale for PGE1 in Erectile Failure - A Survey of Own and World-Wide Experiences. J. Urol. Vol.155., 802-815, 1996

Wissenschaftliche Publikationen 1997

  1. Fabra, M., Frieling, A., Porst, H., Schneider, E.: Single Potential Analysis of Corpus Cavernousm Electromyography for the Assessment of Erectile Dysfunction: Provocation, Reproducibility and Age Dependence - Findings in 36 Healthy Volunteers and 324 Patients. J. Urol. Vol 157, 444-450, 1997

  2. Porst, H.: Benigne Prostatahyperplasie (BPH) - Eine StandortbestimmungForschung und Praxis der Ärztezeitung, 246, 20-22, 1997

  3. Porst, H.: Transurethral Alprostadil with MUSETM (Medicated Urethral System for Erection versus Intracavernous Alprostadil - A Comparative Study in 103 Patients with Erectile Dysfunction. Int. Journal of Impotence Res. 9, 187-192, 1997

  4. Porst, H. Editorial Comment: Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Chew, K.K. et al. Int. J. Impotence Res. 9, 229-230, 1997

Wissenschaftliche Publikationen 1998

  1. Porst, H.: Transurethrale Alprostadilapplikation mit MUSETM (Medicated Urethral System for Erection.- Aktuelle Übersicht und eigene Erfahrungen. Urologe A, 37, 410-416, 1998

  2. Porst, H.: Therapie der erektilen Dysfunktion. Neuromodulatorische und molekulare Grundlagen. NBP Sonderausgabe Erektile Dysfunktion S. 13-31, 1998

  3. Williams, G., Abbou, C.C., Amar, E.T., Desvaux, P., Flam, T.A., Lychlama áNijeholt, G.A.B., Lynch, S.F., Morgan, R.J., Müller, S.C., Porst, H., Pryor, J.P.,Ryan, P., Witsch, U.K.F., Hall, M.M., Place, V.A., Spivack, A.P., Gesundheit, N. onbehalf of the MUSE Study Group. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br. J. Urol. 81, 889-894, 1998

  4. Porst, H.: The potential of Sildenafil (ViagraTM) for salvage therapy in severe male impotence. Int. J. Impotence Res, 10, Suppl3, 67, 1998

  5. Porst, H.: Comparison of the International Index of Erectile Function (IIEF) with the diagnostic outcome in male impotence. Int. J. Impotence Res. 10 Suppl.3, 67, 1998

  6. Porst, H.: Orale Pharmakotherapie der erektilen Dysfunktion. Urologie u.Nephrologie 10, 136-141, 1998

  7. Porst, H.: Lokale Pharmakotherapie der erektilen Dysfunktion. Urologie u. Nephrologie 10, 142-146, 1998

  8. Porst, H.: Edidorial. Sildenafil (ViagraTM) bei erektiler Dysfunktion. Medikament und Lifestyledroge zugleich Münch. med. Wschr. 140, 415-416, 1998

  9. Porst, H., Buvat, J., Meulemann, E., Michal, V., Wagner, G.: Intracavernous Alprostadil Alfadex – an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study, Int. J. Impot. Res. 10 (4): 225 -231, 1998

  10. Williams, G., Abbou, CC., Amar, ET., Desvaux, P., Flam, TA., Lycklama Nijholt, GA., Lynch, SF., Morgan, RJ., Muller, SC., Porst, H., Pryor, JP., Ryan, P., Witzsch, UK, Hall MM, Place, VA., Spivack, AP., Todd, LK.: The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction and ther partners. Muse Study Group, Br. J. Urol., 82(6): 847-54, 1998

  11. Porst, H.: Transurethral alprostadil administration with MUSE (“Medicated Urethral System for Erection”). Current overview and personal expieriences, Urologe A, 37(4):410-6, 1998

  12. Fabra, M., Frieling, A., Porst, H., Schneider, E.: Provozierbarkeit von Signalen des CC-EMG als Parameter in der Diagnostik der erektilen Dysfunktion. Urologe A, 37(3): 287-93, 1998

  13. Williams, G., Abbou, CC., Amar, ET., Desvaux, P., Flam, TA., Lycklama Nijholt, GA., Lynch, SF., Morgan, RJ., Muller, SC., Porst, H., Pryor, JP., Ryan, P., Witzsch, UK, Hall MM, Place, VA., Spivack, AP., Todd, LK.: Effecacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group, Br. J. Urol., 81(6): 889-94, 1998

  14. Fabra, M., Porst, H.: Bulbocavernosus-reflex latencies and pudendal nerve SSEP compared to penile vascular testing in 669 patients with erectile failure and other sexual dysfunction. Int. J. Impotence Res. 10, 167-175, 1998

Wissenschaftliche Publikationen 1999

  1. Meghdadi, S., Porst, H., Stackl, W., Friehe, H., Rodrigues, M., Sinzinger, H.: Presence of PGE 1 binding determines the erectile response to pGE 1. Prostaglandins, Leukotrienes and Essential Fatty Acids. 60 (2), 111-113, 199

  2. Fabra, M., Porst, H.: Bulbocavernosus-reflex latencies and pudendal nerve SSEP compared to penile vascular testing in 669 patients with erectile failure and other sexual dysfunction, Int. J. Impotence Res., 11(3), 167-75, 1999
  3. Porst, H. Editorial Comment to : McMahon, CG., Samali, R., Johnson, H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy, J Urol 162(6), 1992-1998, 1999

Wissenschaftliche Publikationen 2000

  1. Porst, H.: IC351, ein neuer selektiver PDE 5 Inhibitor - Ergebnisse einer placebo-kontrollierten Multicenter Studie in der Indikation erektile Dysfunktion. Urologe A 39, Suppl.1, S 118, P 8.7, 2000

  2. Guiliano, F., Meulemann, E., Saoud, J., Ferguson, K., Whitaker, S., Porst, H.: Daily IC351 treatment of erectile dysfunction, Eur. Urol.37, Suppl.2, 80. abstr. 320, 2000

  3. Porst, H.: Re-dosing of Prostaglandin E1 versus prostaglandin-E1 plus phentolamin in male erectile dysfunction: a dynamic color power Doppler study. Int. J. Impot. Res., 12(2):134-5, 2000

  4. Behrends, S., Steenpass, A., Porst, H., Scholz, H.: Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum. Biochem. Pharmacol., 59(6): 713-717, 2000

  5. Porst, H.: Intracavernosal therapy for erectile failure, impact of treatment and reason for drop-out and dissatisfaction, Int. J. Impot. Res., 12(2):131, 2000

  6. Guiliano, F., Porst, H., Padma-Nathan, H., Saoud, J., Ferguson, K., Whitaker, S., Pullman, W., Rosen, R.: Daily and on-demand IC351 treatment of erectile dysfunction, J Urol. 163, Suppl. 4, 201, 2000

  7. Porst, H.: Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int. J. Impot. Res., Suppl. 4, 91-100, 2000

  8. Eid, JF., Nehra, A., Andersson, KE., Heaton, J., Lewis, RW., Morales, A., Moreland, RB., Mulcahy, JJ., Porst, H., Pryor, JL., Sharlip, I., Wagner, G., Wyllie, M.: First international conference on management of erectile dysfunction. Overview consensus statement. Int. J. Impot. Res., Suppl. 4, 2-5, 2000

Wissenschaftliche Publikationen 2001

  1. Porst, H., Editorial Comment to: Prognostic Factors for Response to Sildenafil in Patients with Erectile Dysfunction von Martinez-Jabalovas, J., Gil-Salom, M., Villamon-Fort, R., Pastor-Hernández, F., Martine-Garcia, R., Eur. Urol. 40, 641 - 647, 2001

  2. Porst, H. et al, Vardenafil Demonstrated Similar Efficacy And Tolerability Among Older And Younger Patients With Marginal Differences In PK Characteristics Between Age Groups. Int. J of Imp. Res 13, Suppl. 4:45, 2001

  3. Porst, H., Rosen R., Padma-Nathan, H., Goldstein, I., Guiliano, F., Ulbrich, E. Bandel, T., and the Vardenafil Study Group: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodisesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impotence Res.: 13, 192 -199, 2001

  4. Stief, C., Juennemann, K-P., Krause, W., Lenk, S., Porst, H., Weidner, W., Buehmann, W., Schalkhäuser, K., Alken, P., Hertle, L., Müller, S., Rübben, H.: Leitlinien zur Diagnostik und Therapie von Libido-und Erektionsstörungen. Urologe A, 40(4), 331-339, 2001

  5. Porst, H.: Editorial Comment to : Stark, S., Sachse, R., Liedl, T., Hensen, J., Rohde, G., Wensing, G., Horstmann, R., Schrott, KM,., Pescatori, ES., Montorsi, F.: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. European Urology, 40(2), 181-190, 2001

  6. Porst, H.: Editorial Comment to Martinez-Jabaloyas, J.M. et al: Prognostic Factors for Response in Patients With Erectile Dysfunction. Eur Urol. 40, 647, 2001

  7. Porst, H.: What will the new competitors of Viagra bring? MMW Fortschr. Medizin, 143 (25), 14, 2001

  8. Porst, H., Rosen, R., Padma-Nathan, H., Goldstein, I., Giuliano, F.: Vardenafil Study Group: Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function irrespective of the baseline severity and aetiology of ED or age of patient, Eur. Urol.39, Suppl.5, 17, abstr. 57, 2001

  9. Muller, MJ., Ruof, J., Graf-Morgenstern, M., Porst, H., Benkert, O.: Quality of partnership in patients with erectile dysfunction after sildenafil treatment, Pharmacopsychiatry, 34 (3):91-95, 2001

  10. Young, J., Auerbach, S., Porst, H.: Vardenafil, a new selective PDE5 inhibitor, significantly improved all IIEF domains and showed a favourable safety profile in patients with erectile dysfunction over 12 weeks, J. Urol. 165 Suppl., 224, abstr. 924, 2001

  11. Porst, H.: Editorial Comment to: Perimenis, P., Gyftopoulos, K., Athanasopoulos, A., Barbalias, G.: Diabetic impotence treated by intracavernosal injections: High treatment compliance and increasing dosage of vaso-active drugs, Eur. Urol., 40 (4), 398-403, 2001

  12. Porst, H., Giuliano, F., Lenk, V., Feldman, R., Steidle, C.: Proportion of successful Sexual intercourses increases after Treatment with Vardenafil, Int J Impot Res, Podium Abstract 89, Suppl. 4, 33, 2001

  13. Porst, H., Giuliano, F., Lenk, V., Feldman,R., Steidle, C.: Proportion of successful sexual intercourses increases after treatment with vardenafil.

Wissenschaftliche Publikationen 2002

  1. Porst, H.: Restoring a Normal Sexual Response: The Ultimate Goal of Erectile Dysfunction Therapy, European Urology Suppl. 1, 19-24, (2002)

  2. Porst, H., IC351 (tadalafil, Cialis): update on clinical experience, Int. J. Impotence Res.14, Suppl., 57 – 64, 2002

  3. Porst, H., Giuliano, F., Liyanage, N.: 6 Month Study Shows Sustained Efficacy of Vardenafil in Treating ED. Int. J. Impotence Res., 14, Suppl.4, S16 , PS-4-5, 2002

  4. Giuliano, F., Porst, H., Shen, W., Chan, S.: Safety and Efficacy of CialisTM (Tadalafil) Taken Daily for the Treatment of Erectile Dysfunction. Int. J. Impotence Res. 14, Suppl. 4, S16, PS-4-6, 2002

  5. Porst, H., Padma-Nathan, H., Thibonnier, M., Eardley, I.: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Eur. Urol. Supplements, 1, 152, abstr. 599, 2002

  6. Porst, H., Rosen, R., Padma-Nathan, H., Varanese, L., Anglin, G., Giuliano, F.: Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J. Urol 167, Suppl., 177, abstr.709, 2002

  7. Padma-Nathan, H., Porst, H., Eardley, I., Thibonnier, M.: Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy, American J. Hypertension.. 15, 48 A, 2002

  8. Porst, H.: Vardenafil: A viewpoint, Drugs & Aging, Vol 19 (3), 228, 2002

  9. Nehra, A., Pryor, J., Althof, S., Andersson, K-E., Carson, CC., Giuliano, F., Hatzichristou, D., Hedlund, H., Meuleman, E.J., Montorsi, F., Porst, H., Riley, A., Saenz de Tejada, I., Stief, C., Wespes, E.: Second international conference on management of erectile dysfunction: New perspectives on treatment, Int. J. Impotence Res.l 14 (Suppl. 1), 1-5, 2002

  10. Porst, H., Kloner, R. A., Mohan, P., Norenberg, C., Pomerantz, K., Segerson, T., Glasser, S. P.: Cardiovascular Safety of Selective PDE5 Inhibitor Vardenafil in Patients with Erectile Dysfunction; an Analysis of Five Placebo-Controlled Clinical Trials, Int. J. of Impotence Res. 14, Suppl. 4, S67, P-092, 2002

Wissenschaftliche Publikationen 2003

  1. Porst, H., Padma-Nathan, H., Giuliano, F., Anglin, G., Varanese, L., Rosen, R.: Efficacy of Tadalafil for the Treatment of Erectile Dysfunktion at 24 and 36 hours after dosing: A Randomized Controlled Trial, Urology 62(1), 121-125, 2003

  2. Porst, H.: Tadalafil: A Viewpoint by Hartmut Porst, Drugs, 63 (20): 2213-2214, 2003

  3. Porst, H., Young J.M., Schmidt A.C., Buvat, J.: Efficacy and tolerability of vardenafil for treatment of erectile dysfunction patient subgroups, Urology, 62(3): 519-23, 2003

  4. Eisenhardt, A., Sperling, H., Hauck, E., Porst, H., Stief, C., Rübben, H., Müller, N., Siefert, W.: ACE Gene I/D NOS3 G894T Polymorphisms and Response to Sildenafil in Men with Erectile Dysfunction, Urology 62(1), 152 -157, 2003

  5. Sperling, H., Eisenhardt, A., Porst, H., Rübben, H., Siffert, W., Stief, C.: NOS3 G894 Polymorphisms and response to Sildenafil in men with Erectile Dysfunction, Int. J. Impotence Res.15, Suppl.6, PS-1-1, 2003

  6. Porst, H., Arnds, S., Kleingarn, M.: A comparator trial between Sildenafil, Tadalafil and Vardenafil – Preliminary results in 150 patients, Int. J. Impotence Res.15, Suppl.6: S5, PS-2-8, 2003

  7. Porst, H., Arnds, S., Kleingarn, M.: What patients prefer and why – Sildenafil vs. Tadalafil in a real life at home setting. Int. J. Impotence Res.15, Suppl. 6, S 21, PS-3-7, 2003

  8. Porst, H.: A viewpoint in: Curran, M., Keatin, G., Tadalafil, Adis Int. Ltd. 2213-2214, 2003

  9. Porst, H.: Therapie der erektilen Dysfunktion im Jahr 2005, Urologe (A), 42(19), 1330-1336, 2003

  10. Hatzichristou, D., Montorsi, F., Porst, H., Buvat, J., Taylor, T., Bandel, T.: A flexible dose regimen of vardenafil for erectile dysfunction: A placebo controlled trial, Eur. Urol. Supplements 2, 176, abstract 694, 2003

  11. Porst, H., Ahuja, S., Carson, C., Kaufman, J., Wang, C.: Tadalafil is effictive in treating mild to severe erectile dysfunction, Int. J. Impotence Res. Suppl.6, S49, MP-10-7, 2003

  12. Sperling, H., Eisenhardt, A., Virchow, S., Hauck, E., Lenk, S., Porst, H., Stief, C., Wetterauer, U., Rübben, H., Müller, N., Siffert, W.: Sildenafil response is influenced by the G protein ß3 subunit GNB3 C825T polymorphism – a pilot study. J. Urol. 169(3): 1048-1051, 2003 13. Porst, H.: Introduction: Eur. Urol. Suppl.2, 1-2, 2003

Wissenschaftliche Publikationen 2004

  1. Eisenhardt, A., Sperling, H., Hauck, E., Porst, H., Stief, C., Rübben, H., Müller, N., Siefert, W.: ACE Gene I/D and ENOS G894T Polymorphisms and Response to Sildenafil in Men with Erectile Dysfunction, J. Urol. Suppl., p 426, abstr.1615, 2004

  2. Brock, B., Porst, H., Stief, C.G., Beneke, M., Ulbrich, E., Saenz de Tejada, I.: Influence of Prior Sildenafil Use on the Efficacy of Vardenafil in Men with Erectile Dysfunction: Retrospective Analysis of a Two Year Study. J. Urol. 171, Suppl., 240, abstr.906, 2004

  3. Porst, H.: Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. EAU Update Series 2, 56-63, 2004

  4. Porst, H., Kleingarn, M., Arnds, S. : The three PDE 5 Inhibitors Sildenafil, Tadalafil and Vardenafil – Results of a Comparative Preference Trial in 222 Patients With Erectile Dysfunction. J. Urol. 171, Suppl., 315, abstr. 1193, 2004

  5. Porst, H.: Erektile Dysfunktion effektiv behandeln, Der Allgemeinarzt, 26-33, 2004

  6. Porst, H.: Tadalafil – ein neuer Phosphodiesterase-5-Hemmer, Arzneimitteltherapie 22, 65-70, 2004

  7. Porst, H.: Erekile Dysfunktion: Neue Medikamente unter Berücksichtigung der PDE 5 Inhibitoren, Urologe A, 43(7), 820-8, 2004

  8. Carson, C., Giuliano, F., Goldstein, I., Hatzichristou, D., Hellstrom, W., Lue, T., Montorsi, F., Munnarriz, R., Nehra, A., Porst, H., Rosen, R.: The “Effictiveness” scale-therapeutic outcome of pharmacologic therapie ED: an international consensus panel report, Int. J. Impot. Res. 16(3), 207-213, 2004

  9. Stief, C., Porst, H., Saenz De Tejada, I., Ulbrich, E., Beneke, M.: Sustained efficacy and tolerability with vardenafil over 2 years of treatmendt in men with erectile dysfunction, Int. J. Clin. Pract., 58 (3), 230-9, 2004

  10. Padma-Nathan, H., Christ, G., Adaikan, G., Becher, E., Brock, G., Carrier, S., Carson, C., Corbin, J., Francis, S., DeBusk, R., Eardley, I., Hedlund, H., Hutter, A., Jackson, G., Kloner, R., Lin, S., McVary, K., McCullough, A., Nehra, A., Porst, H., Schulman, C., Seftel, A., Sharlip, I., Stief, C., Teloken, C. Original Research – Phosphodiesterase Inhibitor Therapy for ED. J Sex Med.1: 128 – 140, 2004

  11. Hatzichristou, D., Montorsi, F., Buvat, J., Laferriere, N., Bandel, T.J., Porst, H.: The Efficacy and Safety of Flexible-Dose Vardenafil (Levitra) in a Broad Population of European Men. Eur. Urol. 45: 634 – 641, 2004

  12. Porst, H.: Vardenafil 10mg improves erectile dysfunction from within 30 minutes to greater than 6 hours after dosing: Results of the “Safety, Tolerability, Efficacy of Vardenafil 10mg in patients with erectile DYsfunction (STEADY) Trial, J Sex Med., Suppl.1, 57, abstract 090, 2004

  13. Rosen, R.C., Porst, H., Montorsi, F.: The Premature Ejaculation Prevalence and Attitudes (PEPA) Survey: A Multi-National Survey. J Sex Med., Suppl.1, 57, Abstract 090, 2004

Wissenschaftliche Publikationen 2005

  1. Porst, H., Lunglmayr, G.: Die Wirksamkeit und Verträglichkeit von Vardenafil im Zeitfenster von sechs Stunden nach Einnahme und darüber hinaus. Ergebnisse einer klinischen Studie in 233 urologischen Praxen. MMW Fortschritte der Medizin 147, 27-32, 2005

  2. Hatzichristou, D., Cuzin, B., Martin-Morales, A., Buvat, J., Porst, H., Laferriere, N., Bandel, T.J., Montorsi, F., Vardenafil Improves Satisfaction Rates, Depressive Symptomatology, and Self-Confidence in a Broad Population of Men with Erectile Dysfunction, J Sex Med. 2, 109-116, 2005

  3. Porst, H., Lunglmayr, G.: Erektionsprobleme lassen sich beheben. MMW Fortschr. Med.147, 43, 2005

  4. Giuliano, F., Porst, H., Hedelin, H., Martin-Morales, A., Sobel, R., Reynolds, R., Glasser, D.: Cardiovascular Safety of Viagra: results of the International Men’s Health Study. Eur. Urol. Supplements 4, 137, abstr. 540, 2005

  5. Porst, H., Tomlin, M., Wylie, K., Colpi, G., Krajka, K., Denne, J., Denes, B.: Satisfaction with the hardness of erection and with the overall sexual experience in patients treated with tadalafil, J Sex Med, Suppl. 1, 85 abstract P-164, 2005

  6. Porst, H., Valiguette, L., Young, J., Moncada, I., Vezina, J.-G., Shahan, B., Edmunds, K., Montorsi, F.: Reliability and safety of vardenafil 10mg for the treatment of erectile dysfunction (RELY I) trial. J Sex Med, Suppl. 1, 61, abstract P-079, 2005

  7. Porst, H., Jacob, G., Albrecht, S.: A comparaive, cross over study to asses the efficacy and safety of Apomorphine and Sildenafil in men with erectile dysfunction, J Sex Med., Suppl. 1, 36, abstract MP-5-5, 2005

  8. Porst, H.: The 3 PDE 5 inhibitors sildenafil, tadalafil and vardenafil in patients with diabetes and ED-results of a comparative trial in 107 patients, J Sex Med., Suppl.1, 21 abstract PS-5-4, 2005

  9. Porst, H.: Factors related to seeking treatment for premature ejaculation: Results from the premature ejaculation prevalence and attitudes (PEPA) survey, J Sex Med, 9, abstract PS-3-2, 2005

Wissenschaftliche Publikationen 2006

  1. Shabsigh, R., Seftel, A., Rosen, R.C., Porst, H., Ahuja, S. Deeley, M.C., Garcia, C.S., Giuliano, F.: A Review of the Time of Onset and Clinical Efficacy of Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction.Urology 2006, in press

  2. Porst, H., Sharlip, I.D., Hatzichristou, D., Rubio-Aurioles, E., Gittlman, M., Stancil, B.-N., Smith, P.M., Wilkins, J., Pommerville, P. for the Vardenafil Study Group.: Extended Duration of Efficacy of Vardenafil When Taken 8 Hours Before Intercourse: A Randomized, Double-blind , Placebo-controlled Study. Eur. Urol. 50, 1086-1095, 2006

  3. Porst, H., Giuliano, F., Glina, S., Ralph, D., Casabé, A.R., Elion-Mboussa, A., Shen, W., Whitaker, S.: Evaluation of the Efficicay and Safety of Once a Day Dosing of Tadalafil 5 mg and 10 mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Eur. Urol. 50, 351-359, 2006

  4. Rubio-Aurioles, E., Porst, H., Eardley, I., Goldstein, I. for the Vardenafil-Sildenafil Comparator Study Group: Comparing Vardenafil and Sildenafil in the Treatment of Men with Erectile Dysfunction and Risk Factors for Cardiovascular Disease: A  Randomized, Double Blind, Pooled Crossover Study. J.Sex Med.3, 1086-1095. 2006

  5. Porst, H., Sharlip, I., Hatzichristou, D., Rubio-Aurioles, E., Gittleman, M. Stancil, BN., Wilkins, HJ., Pommerville, P.: Efficacy and tolerability of flexible-dose vardenafil when taken 8 hours before intercourse: The extended duration of vardenafil in erectile dysfunction (extend) trial. J. Sex Med.3 (Suppl.3), 8, abstract PS-02-012, 2006

  6. Porst, H.: Diagnosis-Related Outcome of the Efficacy and Preference among the 3 PDE 5 Inhibitors in Chronic ED-Results in 484 Patients, J Sex Med, 3 (suppl. 1), 53, abstract 124, 2006

  7. Shabsigh, R., Seftel, A.D., Rosen, R.C., Porst, H., Ahuja, S., Deeley, M.C., Garcia, C.-S., Giuliano, F.: Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 68(4):689-96., 2006

Wissenschaftliche Publikationen 2007

  1. Porst, H., Montorsi, F., Rosen, R.C., Gaynor, L. Grupe, S., Alexander, J.: The Premature Ejaculation Prevalence and Attitudes (PEPA) Survey: Prevalence, Comorbidities, and Professional Help-Seeking. Eur. Urol 51, 816-824, 2007

  2. Porst, H., Behre, H.M., Jungwirth, A., Burkart, M.: Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunctionan open, randomized cross-over study with flexible dosing. Eur J Med Res., 12 (2): 61-7, 2007

  3. Porst, H., Gilbert, C., Collins, S., Huang, X., Symonds, T., Stecher, V.: Development and validation of the quality of erection questionnaire, J Sex Med, 4,372-381, 2006

  4. Stief, C.G., Porst, H., Evers, T., Ulbrich, E.: Vardenafil in the treatment of symptomatic benign prostatic hyperplasia. J Urol 177, No.4, Suppl, 517 abstract 1565, 2007

Wissenschaftliche Publikationen 2008

  1. Rubio-Aurioles, R., Porst, H., Eardley, I., Goldstein, I.: A comparison of vardenafil and sildenafil: Treatment prference and satisfaction among men with ED and related comorbidities. J Sex Med 5 (Suppl.2), 77 abstract MP-02-095, 2008

  2. Porst, H., Rajfer, J., Casabe, A., Feldman, R., Ralph, D., Vieiralves, L., Eder, A., Klise, S.: Long-term safety and efficacy of 5 mg tadalfil dosed once daily in me with erectile dysfunction. J Sex Med 5 (Suppl.2) 62 abstract P-06-053, 2008

  3. Zumbé, J., Porst, H., Sommer, F., Grohmann, W., Beneke, M., Ulbrich, E.: Comparable efficacy of once-daily vs. on-demand vardenafil in men with mild or mild-to moderate ED: The RESTORE study. J Sex Med 5 (Suppl.2) 64 abstract P-06-058, 2008

  4. Stief, C.G., Porst, H., Neuser, D., Beneke, M., Ulbrich, E.A.: Vardenafil improves erectile function and quality of life in men with benign prostatic hyperplasia: A randomised, placebo-controlled study. J Sex Med 5 (Suppl.2) 130 abstract PP-08-267, 2008

  5. Mittleman, M.A., Maclure, M., Lewis, M., Hall, G., Moore, N., Giuliano, F., Porst, H., Hedelin, H., Martin-Morales, A., Sobel, R.E., Reynolds, R., Glasser, D.B.: Cardiovascular outcomes among sildenafil users: results of the International Men’s Health Study. Int J Clin Pract 2008, 62, 3, 367-373

  6. Porst, H., Sandner, P., Ulbrich, E.: Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Current Prostate Reports 2008, 6, 24-30

  7. Stief, C.G., Porst, H., Neuser, D., Beneke, M., Ulbrich, E.A., Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2008 Feb 4; [Epub ahead of print]

  8. Giuliano, F., Patrick, D.L., Porst, H., La Pera, G., Kokoszka, A., Merchant, S., Rothman, M., Gagnon, D.D., Polverejan, E.; for the 3004 Study Group. Premature Ejaculation: Results from a Five-Country European Observational Study. Eur Urol. 53, 1048-1057, 2008

  9. Porst, H., Giuliano, F., Patrick, D.L., La Pera, G., Kokoska, A., Merchant, S., Rothman, M., Gagnon, D.D., Polverejan, E.: Impact of premature ejaculation (PE) on female partners: Results from a 5 country European observational study. Eur Urol 7 (3) 465, abstract 462, 2008

  10. Zumbé, J., Porst, H., Sommer, F., Grohmann, W., Beneke, M., Ulbrich, E.: Comparable Efficacy of Once-Daily Versus On-Demand Vardenafil in Men with Mild-to-Moderate Erectile Dysfunction: Findings of  the RESTORE-Study.Eur.Urol. 54,204-212, 2008

  11. McMahon CG; Althof S; Waldinger MD; Porst, H.; Dean J; Sharlip I; Adaikan PG; Becher E; Broderick GA; Buvat J; Dabees K; Giraldi A; Giuliano F; Hellstrom WJ; Incrocci L; Laan E; Meuleman E; Perelman MA; Rosen R; Rowland D; Segraves R adn the International Society for Sexual Medicine Ad Hoc Committee for Definition of Premature Ejaculation “An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. “BJU international; 102 (3);  338-50, 2008

  12. McMahon CG; Althof SE; Waldinger MD; Porst, H.; Dean J; Sharlip ID; Adaikan PG; Becher E; Broderick GA; Buvat J; Dabees K; Giraldi A; Giuliano F; Hellstrom WJ; Incrocci L; Laan E; Meuleman E; Perelman MA; Rosen RC; Rowland DL; Segraves R: An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. Journal of Sexual Medicine, 5 (7);  1590-1606, 2008  

  13. Porst, H., Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR.: Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008 5(9):2160-2169.

Wissenschaftliche Publikationen 2009

  1. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L.: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009 Oct;56(4):727-35.

  2. Rubio-Aurioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, Wong DG: Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009 May;6(5):1314-23.

  3. Porst H: Review :Premature Ejaculation (in German) Urologe A. 2009 ,48(6):663-74.

  4. Porst H: Once daily therapy of erectile dysfunction. "Flexible love life without time constraints"] (in German) MMW Fortschr Med. 2009 Jun 4;151(23):55

  5. Porst H, Hell-Momeni K, Büttner H: Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil. Urologe A. 2009 ,48(11): 1320-1329.

Wissenschaftliche Publikationen 2010

  1. Porst H, Vardi Y, Akkus E, Melman A, Park NC, Seftel AD, Teloken C, Wyllie M.: Standards for clinical trials in male sexual dysfunctions.. J Sex Med. 2010 7(1 Pt 2):414-44

  2. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aquilina JW, Tesfaye F, Rivas DA.: Baseline Characteristics and Treatment Outcomes for Men with Acquired or Lifelong Premature Ejaculation with Mild or No Erectile Dysfunction: Integrated Analyses of Two Phase 3 Dapoxetine Trials. J Sex Med. 2010 Apr 20. [Epub ahead of print]

  3. Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B.Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction.J Sex Med. 2010 7(10):3487-94

  4. Eisenhardt A, Stief C, Porst H, Wetterauer U, Weidner W, Rübben H, Sperling H.Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population.Andrologia. 2010;42(4):218-24

  5. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011 Jan;8(1):284-93

  6. Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, Broderick G, Burnett A, Buvat J, Dean J, Donatucci C, Eardley I, Fugl-Meyer KS, Goldstein I, Hackett G, Hatzichristou D, Hellstrom W, Incrocci L, Jackson G, Kadioglu A, Levine L, Lewis RW, Maggi M, McCabe M, McMahon CG, Montague D, Montorsi P, Mulhall J, Pfaus J, Porst H, Ralph D, Rosen R, Rowland D, Sadeghi-Nejad H, Shabsigh R, Stief C, Vardi Y, Wallen K, Wasserman M.J: Summary of the recommendations on sexual dysfunctions in men. Sex Med. 2010 Nov;7(11):3572-88

  7. Porst H. The future of erectile dysfunction (ED).Arch Esp Urol. 2010 Oct;63(8):740-747

Wissenschaftliche Publikationen 2011

  1. Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, Rosen RC, Sadovsky R, Waldinger M, Becher E, Broderick GA, Buvat J, Goldstein I, El-Meliegy AI, Giuliano F, Hellstrom WJ, Incrocci L, Jannini EA, Park K, Parish S, Porst H, Rowland D, Segraves R, Sharlip I, Simonelli C, Tan HM; International Society for Sexual Medicine. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation.J Sex Med. 2010 Sep;7(9):2947-69

  2. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, Tesfaye F, Rothman M, Rivas DA, Porst H: Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.Sex Med. 2011;8(2):524-39.

  3. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aquilina JW, Tesfaye F, Rivas DA.; Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. J Sex Med. 2010;7(6):2231-42.

  4. Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C, Shane MA, Sorsaburu S.A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. J Sex Med. 2011;8(9):2617-24

  5. Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team.Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011 Nov;60(5):1105-13

  6. McMahon CG, Porst H: Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. J Sex Med. 2011 ;8(10):2707-25.

  7. Porst H.:An overview of pharmacotherapy in premature ejaculation. J Sex Med. 2011;8 Suppl 4:335-41.Review

  8. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. :Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol. 2011 Oct;60(4):809-25. Epub 2011 Jun 29. Review

  9. Jannini EA, Porst H.:Case studies. A practical approach to premature ejaculation. J Sex Med. 2011 t;8 Suppl 4:360-7

  10. Jannini EA, Porst H.:A practical approach to premature ejaculation. Introduction: the asynchronous couple.J Sex Med. 2011 Oct;8 Suppl 4:301-3.

Wissenschaftliche Publikationen 2012

  1. Porst H, Hell-Momeni K, Büttner H.Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. Expert Opin Pharmacother. 2012 13(10):1481-94

  2. Eusebio Rubio-Aurioles; Hartmut Porst; Edward D Kim; Francesco Montorsi; Geoff Hackett; Antonio Martin Morales; Bronwyn Stuckey; Hartwig Būttner; Teena M West; Ngan N Huynh; et al.: A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012, 9, 1418

  3. Hartmut Porst,* Gerald B. Brock, Krysztof Kula , Ignacio Moncada ,Francesco Montorsi, Bruce R. Basson ," Kraig Kinchen ," and Antonio Aversa: Effects of Once-Daily Tadalafil on Treatment Satisfaction, Psychosocial Outcomes, Spontaneous Erections, and Measures of Endothelial Function in Men With Erectile Dysfunction But Naive to Phosphodiesterase Type 5 Inhibitors. J.Andrology 2012 33(6):1305-2

Wissenschaftliche Publikationen 2013

  1. Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, Hellstrom W, Martin-Morales A, Salonia A, Sharlip I; ISSM Standards Committee for Sexual Medicine.SOP conservative (medical and mechanical) treatment of erectile dysfunction.J Sex Med. 2013 Jan;10(1):130-71.

  2. Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.: Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies. Urology. 2013 Sep;82(3):667-73.

  3. Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med. 2013 Aug;10(8):2044-52

  4. Reisman Y, Eardley I, Porst H; Multidisciplinary Joint Committee on Sexual Medicine (MJCSM).New developments in education and training in sexual medicine.J Sex Med. 2013 Apr;10(4):918-23

  5. Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, Marberger M, Montorsi F, Novara G, Oelke M, Porst H, Roehrborn C, Stief C, McVary KT.Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.Eur Urol. 2013 Aug;64(2):228-43

Wissenschaftliche Publikationen 2014

  1. Porst H, Gacci M, Büttner H, Henneges C, Boess F.:Tadalafil Once Daily in Men with Erectile Dysfunction: An Integrated Analysis of Data Obtained from 1913 Patients from Six Randomized, Double-blind, Placebo-controlled, Clinical Studies. Eur Urol. 2014 Feb;65(2):455-64.

  2. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, Porst H, Salonia A, Traish AM, Maggi M. :A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review.Eur Urol. 2014 Jan;65(1):99-112.

  3. Lowenstein L, Salonia A, Shechter A, Porst H, Burri A, Reisman Y.:Physicians' Attitude toward Female Genital Plastic Surgery: A Multinational Survey.J Sex Med. 2014 Jan;11(1):33-9.

Nach oben

Wissenschaftliche Publikationen 2015

  1. 225.Burri A, Porst H.: Results from an online survey investigating ED patients' insights and treatment expectations. Int J Impot Res. 2015 Jul 30. doi: 10.1038/ijir. 2015.14. [Epub ahead of print]  

  2. 226.Lowenstein L, Reisman Y, Tripodi F, Dean J, Shechter A, Porst H Oxford School of Sexual Medicine: how are we doing? J Sex Med. 2015 Jan;12(1):59-65. doi: 10.1111/jsm.12719. Epub 2014 Oct 20  

  3. 227.Lowenstein L, Tripodi F, Reisman Y, Paraskevi SK, Simonelli C, Porst H; EFS/ESSM Exam Committee. J Sex Med. 2014 Sep;11(9):2141-2.  

  4. 228.Buvat J, Hatzichristou D, Boess FG, Büttner H, Gehchan N, Henneges C, Porst H.

  5. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. Int J Clin Pract. 2014 Sep;68(9):1087-99  

  6. 229.Burri A, Giuliano F, McMahon C, Porst H.: Female partner's perception of premature ejaculation and its impact on relationship breakups, relationship quality, and sexual satisfaction. J Sex Med. 2014 Sep;11(9):2243-55